<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|--------------|
| For commercial reagents, provide supplier | No antibodies are used in this research. | \checkmark |
| name, catalogue number and RRID, if available. | | |
| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
| Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | Sample information section, 1 st paragraph, | |
| Primary cultures: Provide species, strain, sex of origin, genetic modification status. | Sample information section, 1 st paragraph | |
| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | Species: mouse Strain: spleen Age: 6-8 weeks old SPF class Supplier: Guangzhou Yancheng Biotechnology Co., Ltd | |
| Animal observed in or captured from the field: Provide species, sex and age where possible | No captured animal is used | \checkmark |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | | \checkmark |
| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | No plants or microbes are used in this research. | ~ |
| Microbes: provide species and strain, unique accession number if available, and source | No plants or microbes are used in this research. | \checkmark |
| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | No human research participants are used in this research. | ~ |
| Provide statement confirming informed consent obtained from study participants. | No human research participants are used in this research. | ~ |
| Report on age and sex for all study participants. | No human research participants are used in this | 1 |

<u>Design</u>

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|--|---|--------------|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | No clinical trials are used in this research. | \checkmark |
| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
| Provide DOI or other citation details if detailed step- | RNA extraction and quality control 1 st paragraph | |
| by-step protocols are available. | Detection and analysis of LC-MS metabonomics 1 st -2 nd paragraph | |
| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
| State whether and how the following have been | | |
| done, or if they were not carried out. | | |
| Sample size determination | Sample information section, 1 st paragraph | |
| Randomisation | Sample information section, 1 st paragraph | |
| Blinding | Sample information section, 1 st paragraph | |
| Inclusion/exclusion criteria | Sample information section, 1 st paragraph | |
| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
| State number of times the experiment was | Methods section | |
| replicated in laboratory | | |
| Define whether data describe technical or biological | Statistical analysis section | |
| replicates | | |
| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | No human participants | ~ |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | No granting ethics approval needed | \checkmark |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | No permit needed | ~ |
| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | This study is not subject to dual use research of concern | ~ |

<u>Analysis</u>

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|--|---|--------------|
| State if sample or data point from the analysis is | | \checkmark |
| excluded, and whether the criteria for exclusion were | | |
| determined and specified in advance. | | |
| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
| Describe statistical tests used and justify choice of tests. | Statistical analysis | |
| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
| State whether newly created datasets are available, including protocols for access or restriction on access. | No newly created datasets. | ~ |
| If data are publicly available, provide accession number in repository or DOI or URL. | http://prime.psc.riken.jp/compms/msdial/main.html# MSP | |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | http://prime.psc.riken.jp/compms/msdial/main.html# MSP | |
| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
| For all newly generated code and software essential for replicating the main findings of the study: | No newly generated code and software | |
| State whether the code or software is available. | | \checkmark |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | \checkmark |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| MDAR framework recommends adoption of | | |
| discipline-specific guidelines, established and | | |
| endorsed through community initiatives. Journals | | |
| have their own policy about requiring specific | | |
| guidelines and recommendations to complement | | |
| MDAR. | | |
| State if relevant guidelines (eg., ICMJE, MIBBI, | ICMJE guidelines were followed, as the journal follows | |
| ARRIVE) have been followed, and whether a checklist | ICMJE recommendations for publication. | |
| (eg., CONSORT, PRISMA, ARRIVE) is provided with | | |
| the manuscript. | | |

Article information: https://dx.doi.org/10.21037/atm-22-3127